A vaccines developer has expanded at Milton Park.
Emergex Vaccines, which works on vaccines against global infectious disease threats including Covid-19, has taken an additional 2,787 sq ft at 66 Innovation Drive, next door to its R&D centre, bringing its total space to 8,724 sq ft.
Storme Moore-Thornicroft, co-founder and chief operating officer, said: “The current Covid-19 pandemic has put vaccines in the spotlight like never before.
“We believe that our vaccine technology can play a critical role in creating safe, effective vaccines that can be rapidly and widely deployed against some of the most pressing disease threats in the world.
“Our expansion at Milton Park, at the heart of the Oxfordshire sciences ecosystem, reflects our continued growth, and we look forward to working in these facilities to further advance our pipeline.”
Philip Campbell, MEPC commercial director, Milton Park, said: “Emergex Vaccines needed expansion space, and we were pleased to accommodate their growth plans.
“The work the team is doing to address serious infectious diseases across the world through its highly innovative vaccine technology is highly impressive, and we were very happy to assist them.”
© Thames Tap (powered by ukpropertyforums.com).
Sign up to receive your free weekly Thames Tap newsletter here.
